Clinical features of the study population
| n: 233 |
| Gender: male 145 (62.2%); female 88 (37.7%) |
| Age: 66±9.7 years |
| UPDRS (TOTAL): 29.9±13 |
| UPDRS III: 20.2±9.18 |
| Exposure time: 5.9±4.1 years |
| Motor fluctuations: 96 (41.2%) |
| DA type: |
| Oral 197 (84.5%) |
| Pramipexole: 116 (49.8%) |
| Ropinirole: 81 (34.8%) |
| Transdermal |
| Rotigotine: 36 (15.5%) |
| DA-LEDD: 202±93.3 |
| MAOI: 154 (66.1%): Rasagiline 148 (63.5%); Selegiline: 6 (2.6%) |
| Amantadine: 15 (6.4%) |
| Levodopa: 175 (75.1%); LD-LEDD: 600.4±317.5 |
| Total LEDD: 723.8±422.2 |
Data are shown as number and percentage for qualitative variables and mean±SD for quantitative variables.
DA-LEDD, dopamine agonist levodopa equivalent daily dose; MAOI, monoaminooxidase-B inhibitor; UPDRS, unified Parkinson's disease rating scale.